Former Amex Healthcare CFO Accepts Board and Management Position at Endovasc.Business Editors & Health/Medical Writers
MONTGOMERY, Texas--(BUSINESS WIRE)--Oct. 29, 2002
Endovasc Ltd. Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :ENVC) - a biotechnology company with two cardiovascular drugs approved for final FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. Phase III human trials - announced today that the former Chief Financial Officer for the Amex-listed Surgicare Inc. (AMEX AMEX
See: American Stock Exchange :SRG SRG
In currencies, this is the abbreviation for the Suriname Guilder.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ), Robert J. Horn, has joined the company as a new managing director-finances who will represent the company's funding efforts and AMEX listing application.
Mr. Horn has assumed the immediate responsibility for the oversight of Endovasc's American Stock Exchange American Stock Exchange (AMEX)
Stock exchange in the U.S. Originally known as “the Curb,” it began as an outdoor marketplace in New York City c. 1850. It moved indoors to its present location in the Wall Street area in 1921. application. He will assist the company in dealing with the public markets, where he will be able to draw upon his 30+ years of senior management and financial expertise gained through working within the banking industry and as an executive and consultant to both public and private companies.
In addition, Mr. Horn will work on coordinating the structures and pricing for future spin-offs as well as Phase III human trials budgeting.
Prior to joining Endovasc, Mr. Horn has served as the chief financial officer for Amex-listed Surgicare. He also recently served as CFO See Chief Financial Officer. for ebaseOne Corporation, helping it to raise significant venture capital, building the technology company's market cap to over $200 million.
Mr. Horn has spent most of his career as a commercial banker at the executive level, most notably as the long time president & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of First City Bank in Houston. He is widely considered to be one of the foremost authorities on electronic cash management systems.
"Bob Horn is a very well known Houstonian and highly respected within the financial community both locally and nationally," says Dr. David P. Summers, chief executive officer of Endovasc. "We are excited to have him as a member of our team. His many years of banking experience, coupled with his biotech experience, his understanding of public markets and the ability to raise capital will be invaluable for us. He will be a real asset to Endovasc as we move through the Phase III trials with two major cardiovascular drugs, Liprostin(TM) and ANGIOGENIX(TM)."
Mr. Horn received a BA in business administration from Arizona State University Arizona State University, at Tempe; coeducational; opened 1886 as a normal school, became 1925 Tempe State Teachers College, renamed 1945 Arizona State College at Tempe. Its present name was adopted in 1958. . He received post-graduate money and banking training from BAI. He has also been certified to execute NAFTA NAFTA
in full North American Free Trade Agreement
Trade pact signed by Canada, the U.S., and Mexico in 1992, which took effect in 1994. Inspired by the success of the European Community in reducing trade barriers among its members, NAFTA created the world's transactions by the Export-Import Bank.
Endovasc's products include Angiogenix(TM), the revolutionary new treatment that has shown to recruit the body's own stem cells that help grow new heart vessels to relieve chest pain and improve heart function; Liprostin(TM), a liposomal prostaglandin-based treatment that studies suggest will prevent restenosis (re-blockage of arteries), increase circulation, and reduce leg pain due to poor blood flow; biodegradable stents; drug-delivery stents; and newly discovered nutraceutical applications that may accelerate therapeutic development of muscle mass and prostaglandin balancers to treat obesity in overweight diabetic women. Endovasc believes that its nutraceutical stem-cell recruiters combined with high protein complexes and its prostaglandin precursors for conversion of PGE-1 in the body could become blockbuster nonprescription products, producing positive cash flow even sooner than its later stage drugs because they are not subject to the FDA approval process.
Endovasc Ltd. Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The company's pipeline of products and processes include: Liprostin(TM), ANGIOGENIX(TM), PROStent(TM) stent-coating technology, and a biodegradable stent prosthesis prosthesis (prŏs`thĭsĭs): see artificial limb.
Artificial substitute for a missing part of the body, usually an arm or leg. .
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com (Investor questions and requests for materials can be submitted at InvestorRelations@endovasc.com.)